abstract |
The present invention relates to stromal cell-derived factor-1 (SDF-1) peptides or mutant SDF-1 peptides that retain chemoattractant activity but have been mutated to make them resistant to protease digestion. Features a method for treating or ameliorating tissue damage using intravenous administration of a composition (eg, an isolated peptide composition or a stem cell expressing the peptide). [Selection] Figure 1 |